Generate Biomedicines Files U.S. IPO Prospectus, Seeks Up to $425 Million
Generate Biomedicines has submitted paperwork for a U.S. initial public offering that proposes selling 25 million shares at $15 to $17 apiece, a sale that could raise up to $425 million. The Cambridge, Massachusetts-based company, founded in 2018, develops therapeutics by applying machine learning to protein design and lists immunology, oncology an…